ESTRO/LinkedIn
Apr 3, 2025, 09:43
Should NTCP models take the lead in radiation oncology treatment decisions? – ESTRO
ESTRO (European Society for Radiotherapy and Oncology) shared a post on LinkedIn:
“Debate Alert at ESTRO 2025! This house believes that NTCP models should be leading our clinical decision-making
- Date: Saturday, May 3
- Time: 15:15 – 16:30
- Place: Schubert Room
Should Normal Tissue Complication Probability (NTCP) models take the lead in radiation oncology treatment decisions?
Join a dynamic Physics Track debate as leading experts go head-to-head:
For the motion: Markus Alber and Hans Langendijk
Against the motion: Tiziana Rancati and Ivan Vogelius
From opening statements to rebuttals and audience voting, this session promises lively discussion and critical insights into the role of predictive models in patient management.
Who will win? Be there and decide!”
More posts featuring ESTRO.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 1, 2025, 19:08
May 1, 2025, 18:12